Biovaxys Technology Corp (BVAXF)

$0.16 0.00 (N/A)
Market Cap N/A
Revenue (ttm) 0.00
Net Income (ttm) 0.00
EPS (ttm) N/A
PE Ratio N/A
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio N/A
Volume 8,900
Avg Vol 127,880
Day's Range N/A - N/A
Shares Out N/A
Stochastic %K 77%
Beta N/A
Analysts Strong Buy
Price Target N/A

Company Profile

BioVaxys Technology Corp., a clinical-stage biotechnology company, engages in developing viral and oncology vaccine platforms and immuno-diagnostics. The company offers DPX immune educating technology platform and HapTenix neoantigen tumor cell construct platform for treating cancers, infectious diseases, antigen desensitization, and other immune diseases. It also provides Maveropepimut-S (MVP-S), which has completed phase IIb clinical trial for advanced Relapsed-Refractory Diffuse Large B Cell...

Industry: Biotechnology
Sector: Healthcare
Phone: 740-358-0555
Address:
146 Thirtieth Street, Suite 100, Etobicoke, Canada
CptCotton
CptCotton Jun. 11 at 9:18 PM
$BVAXF FUCK THIS. FIX THIS JAMES
0 · Reply
FLArnot
FLArnot Jun. 11 at 8:45 PM
$BVAXF No trade halt update due to late financials. If you can't trade your stock its current value to you is zero. That is bearish not bullish. All the world except USA Pink Slips is halted. They could get a 100 million dollar deal and with the trade halt you see no benefit from it as an investor. Again bearish.
0 · Reply
ProfitWhisperer
ProfitWhisperer Jun. 11 at 4:42 PM
Sona just added a 35-year biotech veteran with GSK, Genentech and Elan background to their board. immuno-oncology commercial experience. the BioVaxys collaboration is getting more institutional muscle around it. $BIOV $BVAXF https://www.sonanano.com/sona-nanotech-appoints-seasoned-biotech-commercial-executive-michael-a-fleming-to-board-of-directors/
0 · Reply
ProfitWhisperer
ProfitWhisperer Jun. 11 at 4:40 PM
$84B+ biotech M&A in Q1 2026. big pharma buying pipelines at scale. DPX platform sitting at the intersection of oncology and infectious disease with peer reviewed data. halt lifts when filing drops. $BVAXF $MRK $AEMD $EBS $REGN
0 · Reply
ProfitWhisperer
ProfitWhisperer Jun. 11 at 4:35 PM
DPX covering oncology AND infectious disease simultaneously. two Nature publications. DoD melanoma funding application. CEPI Ebola submission. one platform, multiple disease categories. $BVAXF $MRK $AEMD $EBS $REGN
0 · Reply
ProfitWhisperer
ProfitWhisperer Jun. 11 at 4:31 PM
CEPI pre-proposal due tomorrow June 12. filing still pending. two catalysts that could completely change the story. $BVAXF $MRK $AEMD $EBS $REGN
0 · Reply
CptCotton
CptCotton Jun. 11 at 2:57 PM
$BVAXF wtf
0 · Reply
FLArnot
FLArnot Jun. 10 at 10:56 PM
$BVAXF I didn't realize when they said the financials would be done by end of May they meant 2027 not 2026. Lift the trade halt by filing. Or at least give an update.
0 · Reply
wheresdannynow
wheresdannynow Jun. 10 at 2:52 PM
$BVAXF Excited to see BioVaxys' DPX platform advancing with solid Phase 2 metastatic bladder results and PESCO data heading to ASCO 2026.
0 · Reply
wheresdannynow
wheresdannynow Jun. 10 at 2:48 PM
$BVAXF is now on my biotech watchlist. Clinical-stage immunotherapy, DPX platform, oncology angle, and the kind of microcap setup that can get violent when volume hits. Watching beside $MRNA $BNTX $IOVA $XBI. High risk. High torque. Eyes open.
1 · Reply
Latest News on BVAXF
No data available.
CptCotton
CptCotton Jun. 11 at 9:18 PM
$BVAXF FUCK THIS. FIX THIS JAMES
0 · Reply
FLArnot
FLArnot Jun. 11 at 8:45 PM
$BVAXF No trade halt update due to late financials. If you can't trade your stock its current value to you is zero. That is bearish not bullish. All the world except USA Pink Slips is halted. They could get a 100 million dollar deal and with the trade halt you see no benefit from it as an investor. Again bearish.
0 · Reply
ProfitWhisperer
ProfitWhisperer Jun. 11 at 4:42 PM
Sona just added a 35-year biotech veteran with GSK, Genentech and Elan background to their board. immuno-oncology commercial experience. the BioVaxys collaboration is getting more institutional muscle around it. $BIOV $BVAXF https://www.sonanano.com/sona-nanotech-appoints-seasoned-biotech-commercial-executive-michael-a-fleming-to-board-of-directors/
0 · Reply
ProfitWhisperer
ProfitWhisperer Jun. 11 at 4:40 PM
$84B+ biotech M&A in Q1 2026. big pharma buying pipelines at scale. DPX platform sitting at the intersection of oncology and infectious disease with peer reviewed data. halt lifts when filing drops. $BVAXF $MRK $AEMD $EBS $REGN
0 · Reply
ProfitWhisperer
ProfitWhisperer Jun. 11 at 4:35 PM
DPX covering oncology AND infectious disease simultaneously. two Nature publications. DoD melanoma funding application. CEPI Ebola submission. one platform, multiple disease categories. $BVAXF $MRK $AEMD $EBS $REGN
0 · Reply
ProfitWhisperer
ProfitWhisperer Jun. 11 at 4:31 PM
CEPI pre-proposal due tomorrow June 12. filing still pending. two catalysts that could completely change the story. $BVAXF $MRK $AEMD $EBS $REGN
0 · Reply
CptCotton
CptCotton Jun. 11 at 2:57 PM
$BVAXF wtf
0 · Reply
FLArnot
FLArnot Jun. 10 at 10:56 PM
$BVAXF I didn't realize when they said the financials would be done by end of May they meant 2027 not 2026. Lift the trade halt by filing. Or at least give an update.
0 · Reply
wheresdannynow
wheresdannynow Jun. 10 at 2:52 PM
$BVAXF Excited to see BioVaxys' DPX platform advancing with solid Phase 2 metastatic bladder results and PESCO data heading to ASCO 2026.
0 · Reply
wheresdannynow
wheresdannynow Jun. 10 at 2:48 PM
$BVAXF is now on my biotech watchlist. Clinical-stage immunotherapy, DPX platform, oncology angle, and the kind of microcap setup that can get violent when volume hits. Watching beside $MRNA $BNTX $IOVA $XBI. High risk. High torque. Eyes open.
1 · Reply
ProfitWhisperer
ProfitWhisperer Jun. 10 at 2:46 PM
vaccine gap for Bundibugyo strain is the key issue. no approved vaccine exists. CEPI pre-proposal deadline June 12. BioVaxys submitting with DPX platform and NIH preclinical data. $BVAXF $MRK $AEMD $EBS $REGN https://x.com/Ebola_Updates/status/2064606969718243587
0 · Reply
ProfitWhisperer
ProfitWhisperer Jun. 10 at 2:41 PM
617 Ebola cases, 117 deaths. CEPI pre-proposal deadline June 12. BioVaxys submitting with DPX platform and NIH preclinical data. no approved Bundibugyo vaccine exists. $BVAXF $MRK $AEMD $EBS $REGN
0 · Reply
ProfitWhisperer
ProfitWhisperer Jun. 10 at 2:38 PM
THT upregulates PD-L1 expression making tumors visible to checkpoint inhibitors. DPX presents the antigens systemically. Sona and BioVaxys building two ends of the same pipeline. $BIOV $BVAXF https://x.com/SonaNanotech/status/2064387267318145393
0 · Reply
FLArnot
FLArnot Jun. 9 at 6:55 PM
$BVAXF All the hype and excitement means nothing under a trade halt order for failure to file. They haven't given an update on the financial filings issue in over a month. Blew past their stated expected completion date, TWICE. And no comment, explanation or new expected date. Last time this happened in May 2024 it was July before trading restarted. Embarrassing to hype a company in this situation.
0 · Reply
Davidendz
Davidendz Jun. 9 at 6:15 PM
$BVAXF Biotech is one of the few sectors where a single catalyst can completely change a company's future. That's why I keep watching names like: $BVAXF $SAVA $ALT $VKTX Small caps. Big outcomes.
1 · Reply
ProfitWhisperer
ProfitWhisperer Jun. 9 at 3:19 PM
DPX platform, NIH preclinical data, Canadian health authority letter of support. BioVaxys going into the CEPI submission with all three. $BVAXF $MRK $AEMD $EBS $REGN
0 · Reply
ProfitWhisperer
ProfitWhisperer Jun. 9 at 3:18 PM
CEPI Bundibugyo call closes June 12. three days left. BioVaxys submitting that day. $BVAXF $MRK $AEMD $EBS $REGN https://x.com/CEPIvaccines/status/2064296708545081426
0 · Reply
ProfitWhisperer
ProfitWhisperer Jun. 9 at 3:15 PM
NK cells confirmed moving into treated tumor tissue in human samples at Dalhousie. hypothesis proven in vivo. local immune activation visible. DPX designed to build on this systemically. $BIOV $BVAXF https://x.com/SonaNanotech/status/2064039135879295011
0 · Reply
ProfitWhisperer
ProfitWhisperer Jun. 9 at 3:14 PM
abscopal effect. THT activates locally, DPX presents systemically. ASCO 2026 validated this mechanism from multiple directions. Sona and BioVaxys building exactly this combination. $BIOV $BVAXF https://x.com/SonaNanotech/status/2064018702039654889
0 · Reply
Davidendz
Davidendz Jun. 8 at 4:02 PM
Everyone is chasing AI and crypto. Meanwhile, biotech quietly keeps producing some of the biggest percentage winners in the market. Watching $BIOV.CSE and $BVAXF alongside $SAVA, $ALT, and $VKTX. The sector has been asleep. That's usually when I start paying attention.
1 · Reply
ProfitWhisperer
ProfitWhisperer Jun. 8 at 3:09 PM
BioVaxys submitting to the first call on June 12. the second call opens another door. the research infrastructure around this outbreak keeps expanding. $BVAXF $MRK $AEMD $EBS $REGN
0 · Reply
ProfitWhisperer
ProfitWhisperer Jun. 8 at 3:08 PM
workstream 2 covers immunological assessment of cross-reactive antibodies from existing Ebola vaccines. DPX NIH preclinical data includes T-cell and immune response data. directly relevant. $BVAXF $MRK $AEMD $EBS $REGN
0 · Reply